Αποτελέσματα Αναζήτησης
15 Ιαν 2024 · People who have interstitial lung disease along with systemic sclerosis are much more likely to die from disease complications than people who do not have lung disease. Around 80% to 90% are alive five years after being diagnosed with interstitial lung disease from systemic sclerosis.
22 Μαΐ 2020 · Despite improved survival, the number one cause of death for most systemic sclerosis–associated interstitial lung disease patients remains respiratory failure from interstitial lung disease.
20 Ιαν 2021 · Review. Epidemiology. The incidence of SSc has been reported only in several European countries as well as the United States (US) and Canada. It is estimated to range between 0.6 and 2.3 per 100,000 individuals in Europe. Notably, in the US and Canada, the reported incidence is slightly higher, ranging between 1.4 and 5.6 per 100,000 individuals.
15 Ιουν 2024 · When scleroderma affects the heart or lungs, it can cause shortness of breath, decreased exercise tolerance and dizziness. Scleroderma can cause scarring in the lung tissues that may result in increasing shortness of breath over time.
Pulmonary involvement in systemic sclerosis In scleroderma, the two most common types of direct pulmonary involvement are ILD and PH, which together account for 60% of SSc-related deaths [2].
The key elements of scleroderma lung disease involve 1) inflammation (potentially treatable); 2) lung scarring (not reversible but potentially preventable); and 3) blood vessel injury (treatable – see Pulmonary Hypertension).
2 Ιαν 2024 · The spectrum of pulmonary complications of SSc and an approach to their evaluation will be reviewed here. The clinical manifestations, diagnosis, therapy, and prognosis of SSc-associated ILD and PAH are discussed separately.
